Vesicle Therapeutics Inc.

Niwot, CO · Founded 2020 · Biotech · Private

Gene silencing therapy using proprietary gectosome delivery of CRISPR-Cas13a targeting GPR146 for homozygous familial hypercholesterolemia

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Niwot, CO
Founded: 2020
Latest Form D: $800K, Apr 2022
Total capital: $1.9M

Federal grants: $1.1M; 3 awards · 2022–2025; Rank in peer group#266 of 326
Private capital raised: $800K; 1 Form D · last Apr 2022; 54 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 2 pending

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase I · Targeting STAT3 with Novel Thiomorpholino Antisense Oligonucleotides for Cancer Therapy$400K
May 2022Federal grantHealth and Human S · Phase I · Targeting GPR146 for the Treatment of Homozygous Familial Hypercholesterolemia$428K
Apr 2022Private capital raisedForm D · SEC · 1st filing$800K
Jan 2022Federal grantHealth and Human S · Phase I · Development of a Gectosome Therapy for Cardiovascular Diseases$317K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

3months

from Vesicle Therapeutics Inc.’s first federal award to its first private round.

First federal award · Jan 2022: Health and Human S · $317K
First Form D · Apr 2022: $800K · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Linked publications#2 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Xuedong LiuDirector, Executive OfficerNamed in SEC Form D filings
Donna PeakDirector, Executive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2

PendingNovel Antisense Oligonucleotides Containing Hybrid Morpholino And Dna/rna(modified) With Phosphorothioate (ps) Linker For The Treatment Of Cancer And Autoimmune DisordersUSPTOApplication 63416378
PendingNovel Antisense Oligonucleotides Containing Hybrid Morpholino And Dna/rna(modified) With Phosphorothioate (ps) Linker For The Treatment Of Cancer And Autoimmune DisordersUSPTOApplication 19120920

Recent research by its founders

Dynamics of clinical <i>Klebsiella pneumoniae</i> strains over the COVID-19 pandemic in Qingdao, China20260 cites
Effect of diamond growth mode on nitrogen-vacancy distribution20260 cites
Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor20260 cites

IKAIKA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
MINTECH-BIO, INC.Similar federal contract value in Biotech · null in contracts
ARIZONA CANCER THERAPEUTICS L.L.C.Similar federal contract value in Biotech · null in contracts
SE3D INC.Similar federal contract value in Biotech · null in contracts
CHEMICAL BIOLOGY PROBES LLCSimilar federal contract value in Biotech · null in contracts
Plexiform Bioscience Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.